Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Phenergan w/ Codeine is a combination oral syrup containing codeine phosphate (opioid antitussive) and promethazine hydrochloride (phenothiazine antihistamine) approved in 1952. It is indicated for cough and upper respiratory symptoms, leveraging codeine's opioid receptor agonism to suppress cough reflex and promethazine's anticholinergic and sedating properties to provide symptomatic relief. This product represents a legacy fixed-dose combination addressing symptomatic cough management in ambulatory patients.
As LOE approaches, brand teams face margin compression and are likely consolidating; opportunities exist in managed care contracting and generic oversight roles rather than growth-oriented positions.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Phenergan w/ Codeine offers limited career acceleration; roles are primarily defensive and focused on managed care negotiations, regulatory compliance, and generic transition management. This is a stabilization play suited for mid-career professionals managing mature portfolio assets rather than growth-oriented early-career advancement.
Worked on PHENERGAN W/ CODEINE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.